NCT05326399 Renal Biopsies in Post-liver Transplantation Patients With Renal Impairment
| NCT ID | NCT05326399 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RenJi Hospital |
| Condition | Liver Transplantation |
| Study Type | OBSERVATIONAL |
| Enrollment | 369 participants |
| Start Date | 2022-06-01 |
| Primary Completion | 2027-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 369 participants in total. It began in 2022-06-01 with a primary completion date of 2027-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Investigators will conduct this single-center, prospective cohort study to explore the prevalence and risk factors of renal function progression in post-liver transplantation patients with renal impairment after renal biospy and to understand the the pathology of kidney disease in post-liver transplantation patients with renal impairment.
Eligibility Criteria
Inclusion Criteria: * age 18-75 years * patients received liver transplantation * new onset of proteinuria(defined as 24-hour proteinuria\>1g/24h, or Urinary albumin creatinine ratio(UACR)\>300mg/g on at least two occasions), and/or renal impairment: eGFR \<60 mL/min/1.73 m² at least two occasions, and/or serum creatinine increase ≥50% from baseline * have received renal biopsy in the past 3 months * Signed informed consent form(ICF) Exclusion Criteria: * patients received renal transplantation * hepatic failure * severe bleeding risk or platelet \<70\*109/L * chronic kidney insufficiency with eGFR\<30ml/min·1.73m2,or kidney atrophy, or solitary kidney, or medullary sponge kidney, or polycystic kidney, or obstructive nephropathy * uncontrolled mental disease or unable to cooperate during operation * Pregnancy or lactation * not suitable for this study judged by investigaters
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05326399 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Liver Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05326399 currently recruiting?
Yes, NCT05326399 is actively recruiting participants. Contact the research team at shan_mou@126.com for enrollment information.
Where is the NCT05326399 trial being conducted?
This trial is being conducted at Shanghai, China, Shanghai, China.
Who is sponsoring the NCT05326399 clinical trial?
NCT05326399 is sponsored by RenJi Hospital. The trial plans to enroll 369 participants.